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Abstract
Arabinomannan (AM) polysaccharides are clinical biomarkers for Mycobacterium tuberculosis (MTB) infections due to their roles
in the interaction with host cells and interference with macrophage activation. Collections of defined AM oligosaccharides can help
to improve the understanding of these polysaccharides and the development of novel therapeutical and diagnostic agents. Auto-
mated glycan assembly (AGA) was employed to prepare the core structure of AM from MTB, containing α-(1,6)-Man, α-(1,5)-Ara,
and α-(1,2)-Man linkages. The introduction of a capping step after each glycosylation and further optimized reaction conditions
allowed for the synthesis of a series of oligosaccharides, ranging from hexa- to branched dodecasaccharides.
Introduction
Bacterial infections caused by MTB killed 1.7 million people in
2017. Additionally, more than 10 million new tuberculosis (TB)
cases were reported, with multidrug-resistant TB accounting for
almost 10% of the registered cases [1]. The development of
novel therapeutic agents and more efficient strategies to detect
MTB infections at an early stage is essential, as an early diag-
nosis would help to prevent most deaths from tuberculosis [1].
AMs, one of the main components of the mycobacterial cell
wall [2], are composed of α-(1,5)-, α-(1,3)- and β-(1,2)-arabi-
noses as well as α-(1,6)- and α-(1,2)-mannosides [3-5]. AMs are
potential clinical biomarkers for infection [6-10] due to their
roles in the interaction with host cells, interference with macro-
phage activation, and immunosuppression of T cell responses
[11,12]. Diagnosis of tuberculosis in patients with HIV coinfec-
tions is possible by immunodetection of AMs and their lipi-
dated lipoarabinomannan (LAM) analogs in urine samples
using the Alere lateral flow urine (LF)-LAM assay [13]. How-
ever, the low sensitivity of the Alere assay limits its scope.
Glycan array screening of more than 100 monoclonal anti-
bodies against more than 60 synthetic glycans related to the
mycobacterial cell wall helped to identify an antibody targeting
the 5-methylthio-ᴅ-xylofuranose AM [7,14]. The Fujifilm
SILVAMP TB LAM immunoassay chip provided a threefold
higher sensitivity than Alere LF-LAM. Still, current technolo-
gies lack sensitivity and are limited to patients coinfected with
HIV [7,10,15]. Identification of novel anti-TB agents that
specifically target AMs with high sensitivity are required. Pure
AM oligosaccharides may help to identify new lead com-
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Scheme 1: Schematic representation of AGA for oligomannosides and oligoarabinomannosides using building blocks 1–3.
pounds for the development of diagnostics. Since the isolation
of pure oligosaccharides from MTB strains in sufficient quanti-
ties is challenging, the chemical synthesis of AM is an attrac-
tive alternative. AM polysaccharides as large as 92-mers as well
as many shorter AM oligomers have been prepared by solution-
phase synthesis [16-20]. These multi-step syntheses are chal-
lenging and time-consuming. AGA reduces time and effort to
access complex glycans [21], including linear and branched
oligoarabinofuranosides α-(1,5)- and α-(1,3)- [22] as well as
arabinomannose [23,24].
Herein, we describe the AGA of oligosaccharides 4–9 that
resemble portions of the MTB AM core structure (Scheme 1).
Just three building blocks, namely 1–3, were required to access
all six oligosaccharides, ranging from hexa- to dodecasaccha-
rides.
Results and Discussion
The automated syntheses of oligomannosides 4–6 and oligoara-
binomannosides 7–9 were performed on a self-built automated
synthesizer using a Merrifield resin functionalized with a photo-
cleavable linker as solid support [25]. A typical AGA cycle
consisted of three modules. The acidic wash module prepared
the resin for glycosylation by quenching any remaining base
from a previous cycle. In the glycosylation module, the thiogly-
coside donor was coupled to the resin upon activation with NIS
and TfOH (from −40 to −20 °C). Finally, the deprotection
module removed the temporary protecting group, such as
fluorenylmethyloxycarbonyl (Fmoc) or levulinoyl (Lev), to
reveal a free hydroxy group that allowed for further chain elon-
gation in the next cycle. Fmoc and Lev were used as orthogo-
nal temporary protecting groups, whereby Fmoc was cleaved by
piperidine (20 vol % in DMF), while Lev was removed using
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Figure 1: HPLC chromatograms of crude dodecamer 9. a) Results obtained with AGA procedure A. b) Results obtained with AGA procedure B. For
detailed procedures, see Tables S10 and S11 in Supporting Information File 1.
hydrazine acetate. Iterative cycles continued until the desired
structure was obtained. The oligosaccharide products were
cleaved from the solid support using a flow UV photoreactor,
followed by a two-step purification and global deprotection
[25].
Linear α-(1,6)-hexamannoside 4 was synthesized using six cou-
pling cycles and 6.5 equiv of mannose building block (BB) 1.
No deletion sequences were observed and the crude product
was purified using normal-phase HPLC to obtain hexamanno-
side 4 in 55% yield, based on resin loading. The doubly
branched hexamannoside 5 was assembled using BB 1 for
α-(1,6) linkages and BB 2 for α-(1,6)/α-(1,2) branching points.
First, the linear α-(1,6)-trimannose was assembled, followed by
deprotection of both Lev and Fmoc to reveal three hydroxy
groups. Three sequential glycosylation cycles using 6.5 equiv of
BB 1 afforded compound 5 in 37% yield. Chromatographic
analysis revealed compound 5 as the major product, along with
pentamer and tetramer side products from incomplete glycosyl-
ation. To improve the glycosylation efficiency, a new glycosyl-
ation module employing higher incubation and reaction temper-
atures (from −20 °C to 0 °C) was introduced (procedure B).
Capping after each glycosylation prevented the formation of
undesired side products [26] and improved the isolated yield of
5 to 53%, with no detectable deletion sequences (Table 1).
The inclusion of a capping step in the AGA synthesis cycle
(procedure B) was further illustrated in the synthesis of oligo-
saccharides 6–9. AGA of the branched 12-mer mannoside 6
showed a dramatic improvement, with yields rising from 6%
Table 1: AGA of arabinomannosides 4–9. Procedure A modules:
i) acidic wash, ii) glycosylation (from −40 °C to −20 °C), and iii) Fmoc/
Lev deprotection. Procedure B modules: i) acidic wash, ii) glycosyla-











(procedure A) to 48% (procedure B). Syntheses of linear
octamer-arabinomannoside 7 and linear 12-mer 8 were
addressed using building block 1 and arabinose BB 3 for the
α-(1,5)-Ara linkage. Procedure A efficiently provided the linear
mannose backbone, but resulted only in partial glycosylation of
arabinose BB 3, thus giving the hexamannoside as main prod-
uct as well as multiple side products missing one or more arabi-
noses. The desired products 7 and 8 were isolated in only 9 and
7% yield, respectively. In contrast, most deletion sequences
were absent and 7 and 8 were isolated in 56 and 61% yield, re-
spectively, when procedure B was employed.
The advantage of the new procedure became more apparent for
AGA of dodecamer 9, which required all three BBs. While pro-
cedure A yielded just 3% dodecamer 9 (Figure 1a), procedure B
gave 9 as the major product (26%, Figure 1b).
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Figure 2: Schematic representation of LAM and AM oligomers obtained using AGA.
The global deprotection of oligosaccharides 4–9 was achieved
by removal of the benzoate ester protecting groups under
Zemplén methanolysis, followed by Pd/C-catalyzed hydro-
genolysis of the carboxybenzyl group and the benzyl ethers.
Mannosides 4–6 were deprotected and purified using reversed-
phase HPLC to obtain fully deprotected mannosides 10–12
(Figure 2). For the arabinomannosides 7–9, the acid-labile
arabinose chain was cleaved during hydrogenation, giving a
complex mixture of deletion sequences lacking one to six arabi-
nose moieties. To overcome this challenge, hydrogenolysis with
Pd(OH)2 was performed to access the fully deprotected arabino-
mannosides 13–15 (Figure 2).
Conclusion
A collection of AM oligosaccharides containing α-(1,6)-Man,
α-(1,5)-Ara, and α-(1,2)-Man was synthesized by AGA using
three monosaccharide building blocks. The linear oligomanno-
sides were readily assembled and isolated in short time and high
yield under standard conditions. The introduction of a capping
step after each glycosylation and optimized reaction conditions
allowed for the synthesis of larger oligosaccharides. The result-
ing oligosaccharides will be used to study the substructure-spe-
cific antibody recognition of arabinomannans.
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